This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fuster, V. Articles by Chesebro, J. H Search for Related Content PubMed PubMed Citation Articles by Fuster, V. Articles by Chesebro, J. H Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLESTEROL Medline Plus Health Information Coronary Artery Disease Social Bookmarking                         What's this?

Atherothrombosis: mechanisms and clinical therapeutic approaches

Mount Sinai Medical Center, New York, NY, USA

Juan Jose Badimon

Mount Sinai Medical Center, New York, NY, USA

James H Chesebro

Mount Sinai Medical Center, New York, NY, USA

Eroded or disrupted atherosclerotic plaques act as a substrate for thrombosis, leading to ischemic coronary artery and cerebrovascular disease. Plaques vary greatly in composition, size, and the degree of stenosis they cause. Plaques can be categorized based on these features, which helps to estimate the likelihood of rupture and subsequent thrombosis. Vascular plaques often begin at regions with low and oscillatory shear forces that cause chronic minimal endothelial damage or dysfunction. Lipoproteins enter the vessel wall, promoting the recruitment of monocytes, which imbibe lipids and become foam cells. Smooth muscle cells invade these early plaques, producing connective tissue fibrils that form a fibrous cap over the lipid center; rupture of this cap is an important cause of thrombosis. Passive plaque disruption occurs when physical forces cause cap rupture; active disruption occurs when the cap is attacked by macrophages and proteolytic enzymes. Tissue factor is one of many factors within plaque that stimulates thrombosis.

Key Words: atherosclerosis • atherothrombosis • fibrin • plaque rupture • platelets • thrombosis

Vascular Medicine, Vol. 3, No. 3, 231-239 (1998)
DOI: 10.1177/1358836X9800300310


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. H. Mandegar, F. Roshanali, and A. Kocharian Complicated course consequences of a floating thrombus in ascending aorta Eur J Echocardiogr, November 1, 2008; 9(6): 846 - 848. [Abstract] [Full Text] [PDF]

				R. Jaumdally, C. Varma, R. J. Macfadyen, and G. Y.H. Lip Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment? Eur. Heart J., April 2, 2007; 28(8): 929 - 940. [Abstract] [Full Text] [PDF]

				W. Dai and R. A. Kloner Relationship Between Cyclooxygenase-2 Inhibition and Thrombogenesis Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 51 - 59. [Abstract] [PDF]

				K. W. Lee and G. Y. H. Lip Effects of Lifestyle on Hemostasis, Fibrinolysis, and Platelet Reactivity: A Systematic Review Arch Intern Med, October 27, 2003; 163(19): 2368 - 2392. [Abstract] [Full Text] [PDF]

				R. P. Tracy Thrombin, Inflammation, and Cardiovascular Disease: An Epidemiologic Perspective Chest, September 1, 2003; 124 (2009): 49S - 57S. [Abstract] [Full Text] [PDF]

				R. Sodian, M. Bauer, Y.-G. Weng, H. Siniawski, A. Koster, and R. Hetzer Floating nonocclusive thrombus in the ascending aorta Ann. Thorac. Surg., August 1, 2002; 74(2): 588 - 590. [Abstract] [Full Text] [PDF]

				M. Fukuhara, R. L. Geary, D. I. Diz, P. E. Gallagher, J. A. Wilson, S. S. Glazier, R. H Dean, and C. M. Ferrario Angiotensin-Converting Enzyme Expression in Human Carotid Artery Atherosclerosis Hypertension, January 1, 2000; 35(1): 353 - 359. [Abstract] [Full Text] [PDF]

				R. A. Shirk, N. Parthasarathy, J. D. San Antonio, F. C. Church, and W. D. Wagner Altered Dermatan Sulfate Structure and Reduced Heparin Cofactor II-stimulating Activity of Biglycan and Decorin from Human Atherosclerotic Plaque J. Biol. Chem., June 9, 2000; 275(24): 18085 - 18092. [Abstract] [Full Text] [PDF]